Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612149 | 0.95 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL16360194 | 0.94 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL27984222 | 0.94 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2TNF | |
| Hydrochloric Acid SCHEMBL28086829 | 0.93 | KMT2A (0.53) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL47693 | 0.91 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL30781736 | 0.91 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL29779340 | 0.91 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL3623157 | 0.91 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14759878 | 0.89 | KMT2A (0.60) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL5497604 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962697-B2 | Bioreponsive polymers | INTERFACE BIOLOGICS INC. (CA) | 2015-02-24 | — | — | US | disclosed |
| US-8703114-B2 | Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-04-22 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20110046348-A1 | METHODS OF PREPARING PEPTIDE DERIVATIVES | KRUSZYNSKI MARIAN | 2011-02-24 | — | — | US | disclosed |
| US-7312306-B2 | Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046348-A1 | METHODS OF PREPARING PEPTIDE DERIVATIVES | DNPEP, PEPD, PTMS | KMT2A 3832/4885FABP5 1620/4885FABP7 1675/4885 |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | LHCGR, GNRHR, FSHR | KMT2A 510/4885FABP5 1254/4885FABP7 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.